기저세포암 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 지역별, 부문별 예측(2024-2030년)

Basal Cell Carcinoma Treatment Market Growth & Trends:

The global basal cell carcinoma treatment market size is anticipated to reach USD 5.93 billion by 2030, growing at a CAGR of 10.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of basal cell carcinoma and the rising geriatric population. The European Skin Cancer Foundation estimates that the incidence of basal cell carcinoma (BCC) is 50 to 80 new cases per 100,000 people in Europe and 250 cases per 100,000 people in Australia annually, with an increasing trend. The increase in the number of cancer cases can primarily be attributed to the growing overall & geriatric population and certain socioeconomic factors.

Technological advancement in the diagnosis and treatment of disease is anticipated to positively impact market growth. With advanced technologies, dermatologists can more accurately diagnose patients and effectively differentiate basal cell carcinoma from other skin lesions. For instance, in 2024, the U.S. FDA approved DermaSensor, an AI-powered light spectroscopy instrument for detecting skin cancer, including melanoma, single cell carcinoma (SCC), and basal cell carcinoma (BCC). This technique can help primary care clinicians identify patients who require rapid attention for a biopsy and specialist care, thereby alleviating high wait times and the shortage of dermatologists in certain places. The growing use of such diagnostic tools is expected to increase the diagnostic and treatment rates in the future, driving demand for medicines used for the treatment of basal cell carcinoma.

Furthermore, the increase in the geriatric population is driving the demand for treatment of BCC, including surgery, radiotherapy, topical chemotherapy, oral medications, and chemical peeling. The main cause of developing BCC is repeated exposure to Ultraviolet (UV) light. The elderly population has a higher chance of acquiring BCC than younger people as they have been exposed to UV rays for longer during their lifetime. Due to aging and reduced immune system function, UV radiation and other carcinogenic factors can break the DNA more easily, increasing the risk of skin cancer, especially BCC, in older persons. According to a study published in the Journal of Geriatric Oncology in 2023, over 100,000 patients with BCC are treated annually in their final year of life in the U.S. However, clinical practice guidelines hardly ever take age & comorbidities into account. Thus, a growing geriatric population is expected to drive market growth during the forecast period.

Basal Cell Carcinoma Treatment Report Highlights:

• The surgery segment held the largest revenue share of the market in 2023. This can be attributed to the increasing incidence and prevalence of disease and the high demand for surgery for treatment owing to high safety and efficacy.
• In topical chemotherapy, the 5-fluorouracil (5-FU) segment held the largest share of the market in 2023. This can be attributed to the development and launch of a novel generic version of 5-fluorouracil (5-FU) to treat BCC patients.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, increasing prevalence of basal cell carcinoma, and favorable regulatory environment for R&D of novel products.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment Type
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Type Outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Basal Cell Carcinoma Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of target diseases
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Rising geriatric population
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Adverse effects associated with treatment.
    • 3.2.2.2. High cost of treatment
• 3.3. Basal Cell Carcinoma Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Basal Cell Carcinoma Treatment Market: Treatment Type Estimates & Trend Analysis

• 4.1. Global Basal Cell Carcinoma Treatment Market: Treatment Type Dashboard
• 4.2. Global Basal Cell Carcinoma Treatment Market: Treatment Type Movement Analysis
• 4.3. Global Basal Cell Carcinoma Treatment Market By Treatment Type, Revenue
• 4.4. Surgery
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Mohs Surgery
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Surgical Excision
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Electrodesiccation and Curettage (ED&C)
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Radiotherapy (RT)
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Intralesional Injections
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Topical Chemotherapy
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.2. 5-fluorouracil (5-FU)
    • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.3. Tirbanibulin (Klisyri)
    • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.4. Imiquimod (Zyclara)
    • 4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Oral Medications
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.2. Vismodegib (Erivedge)
    • 4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.3. Sonidegib (Odomzo)
    • 4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Intravenous Medications
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Chemical Peeling Treatment
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million).

Chapter 5. Basal Cell Carcinoma Treatment Market: Regional Estimates & Trend Analysis By Treatment Type

• 5.1. Regional Dashboard
• 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.3. North America
  • 5.3.1. U.S.
    • 5.3.1.1. Key country dynamics
    • 5.3.1.2. Regulatory framework/ reimbursement structure
    • 5.3.1.3. Competitive scenario
    • 5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.2. Canada
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. Mexico
    • 5.3.3.1. Key country dynamics
    • 5.3.3.2. Regulatory framework/ reimbursement structure
    • 5.3.3.3. Competitive scenario
    • 5.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Germany
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. France
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Italy
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Spain
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Denmark
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Regulatory framework/ reimbursement structure
    • 5.4.6.3. Competitive scenario
    • 5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key country dynamics
    • 5.4.7.2. Regulatory framework/ reimbursement structure
    • 5.4.7.3. Competitive scenario
    • 5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.8. Norway
    • 5.4.8.1. Key country dynamics
    • 5.4.8.2. Regulatory framework/ reimbursement structure
    • 5.4.8.3. Competitive scenario
    • 5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. India
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Australia
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. South Korea
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Brazil
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Argentina
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. South Africa
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. UAE
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.4. Kuwait
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Participant Overview
• 6.3. Financial Overview
• 6.4. Treatment Type Benchmarking
• 6.5. Company Market Share Analysis, 2023
• 6.6. Strategy Mapping
• 6.7. Company Profiles
  • 6.7.1. Bausch Health Companies Inc.
    • 6.7.1.1. Company overview
    • 6.7.1.2. Financial performance
    • 6.7.1.3. Product benchmarking
    • 6.7.1.4. Strategic initiatives
  • 6.7.2. Almirall, S.A.
    • 6.7.2.1. Company overview
    • 6.7.2.2. Financial performance
    • 6.7.2.3. Product benchmarking
    • 6.7.2.4. Strategic initiatives
  • 6.7.3. Genentech, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
    • 6.7.3.1. Company overview
    • 6.7.3.2. Financial performance
    • 6.7.3.3. Product benchmarking
    • 6.7.3.4. Strategic initiatives
  • 6.7.4. Novartis AG.
    • 6.7.4.1. Company overview
    • 6.7.4.2. Financial performance
    • 6.7.4.3. Product benchmarking
    • 6.7.4.4. Strategic initiatives
  • 6.7.5. Regeneron Pharmaceuticals Inc.
    • 6.7.5.1. Company overview
    • 6.7.5.2. Financial performance
    • 6.7.5.3. Product benchmarking
    • 6.7.5.4. Strategic initiatives
  • 6.7.6. Dr Reddy's Laboratories.
    • 6.7.6.1. Company overview
    • 6.7.6.2. Financial performance
    • 6.7.6.3. Product benchmarking
    • 6.7.6.4. Strategic initiatives
  • 6.7.7. Taro Pharmaceuticals Ltd.
    • 6.7.7.1. Company overview
    • 6.7.7.2. Financial performance
    • 6.7.7.3. Product benchmarking
    • 6.7.7.4. Strategic initiatives
  • 6.7.8. Accord Healthcare Limited (Subsidiary of Intas Pharmaceuticals)
    • 6.7.8.1. Company overview
    • 6.7.8.2. Financial performance
    • 6.7.8.3. Product benchmarking
    • 6.7.8.4. Strategic initiatives